The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.
Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.
Department of GU Medicine, St Thomas' Hospital, London.
S
S
Gill
A
A
Tang
M
M
Cordery
B
B
Spacey
G
G
Kelly
N T
NT
Bateman
D
D
Barlow
D000328:Adult; D000704:Analysis of Variance; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D016655:HIV Core Protein p24 / Q000032:analysis*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D010919:Placebos; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D016655:HIV Core Protein p24; D006454:Hemoglobins; D010919:Placebos; D015215:Zidovudine